Scarica l'app Stockscreener
11.22
3.73%
0.365
Precedente Chiudi:
$10.86
Aprire:
$10.99
Volume 24 ore:
2.81M
Relative Volume:
0.59
Capitalizzazione di mercato:
$1.16B
Reddito:
$45.97M
Utile/perdita netta:
$-508.80M
Rapporto P/E:
-2.0484
EPS:
-5.48
Flusso di cassa netto:
$-382.65M
1 W Prestazione:
-0.92%
1M Prestazione:
-2.34%
6M Prestazione:
+16.86%
1 anno Prestazione:
-49.73%
Intervallo 1D:
$10.98
$11.51
Intervallo di 1 settimana:
$10.57
$11.54
Portata 52W:
$5.90
$24.16
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.22 | 1.15B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.51 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.45 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.16 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.45 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
302.86 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Intellia Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Analysts Are Upgrading Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results - Yahoo Finance
Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN
Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Will Intellia Therapeutics Inc. Benefit From Broader Market BounceReal Trader Watchlist of Hot Stocks Released - beatles.ru
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript - MSN
Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates - MSN
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - MSN
Citi Maintains Hold Rating on Intellia Therapeutics with $12 Price Target - AInvest
Intellia Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Have Lowered Expectations For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results - 富途牛牛
Intellia Therapeutics Surpasses Q2 Earnings and Revenue Expectations - AInvest
Wells Fargo Sticks to Their Buy Rating for Intellia Therapeutics (NTLA) - The Globe and Mail
Intellia Therapeutics Reports Q2 2025 Progress and Financials - The Globe and Mail
Wells Fargo Maintains Overweight on Intellia, PT Down to $45 - AInvest
Intellia Therapeutics stock price target lowered to $45 by Wells Fargo - Investing.com Canada
Leerink Partners lowers Intellia Therapeutics stock price target to $41 By Investing.com - Investing.com Canada
Intellia: HC Wainwright Keeps Buy Rating, Lowers PT to $25 from $30. - AInvest
Gene-Editing's Quiet Revolution: Why Intellia Therapeutics Could Redefine Rare Disease Investing - AInvest
INTELLIA THERAPEUTICS, INC. (NTLA) - MSN
Intellia (NTLA) Q2 Revenue Jumps 106% - AOL.com
Intellia Therapeutics Inc (NTLA) Q2 2025 Earnings Call Highlights: Strategic Advancements and Financial Resilience - GuruFocus
Intellia Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Intellia Therapeutics' Momentum in ATTR-CM and HAE Trials: A Catalyst-Driven Path to First-Time Commercial Success - AInvest
Intellia Therapeutics' Q2 2025: Key Contradictions in MERIT Trial Expansion, Cash Runway, and Clinical Study Timelines - AInvest
Intellia Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating - TipRanks
RBC Cuts Price Target on Intellia Therapeutics to $21 From $25, Keeps Outperform Rating - MarketScreener
Intellia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Intellia Therapeutics beats Q2 2025 forecasts - Investing.com India
Transcript : Intellia Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Intellia Therapeutics Announces Executive Retirement - TipRanks
Intellia Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com Australia
Intellia Therapeutics Announces Second Quarter 2025 Financial Re - GuruFocus
Earnings Flash (NTLA) Intellia Therapeutics Posts Q2 Net Loss $0.98 a Share, vs. FactSet Est of $1.02 Loss - MarketScreener
Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q2 Revenue $14.2M, vs. FactSet Est of $11.9M - MarketScreener
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Intellia Reports 98% HAE Attack Reduction in 3-Year Data, Accelerates Phase 3 Enrollment Across Programs - Stock Titan
Intellia Therapeutics shares rise 6.61% intraday as Wall Street recovers from Friday's selloff. - AInvest
How many analysts rate Intellia Therapeutics Inc. as a “Buy”Explosive returns - Jammu Links News
Is Intellia Therapeutics Inc. stock overvalued or undervaluedAchieve rapid wealth accumulation with smart picks - Jammu Links News
What are Intellia Therapeutics Inc. company’s key revenue driversMaximize gains with proven stock analysis - Jammu Links News
What is Intellia Therapeutics Inc. company’s growth strategyTriple-digit return opportunities - Jammu Links News
Why is Intellia Therapeutics Inc. stock attracting strong analyst attentionUnmatched profit potential - Jammu Links News
When is Intellia Therapeutics Inc. stock expected to show significant growthDiscover market opportunities with expert help - Jammu Links News
What is the dividend policy of Intellia Therapeutics Inc. stockAccelerated financial growth - Jammu Links News
Does Intellia Therapeutics Inc. stock perform well during market downturnsMaximize gains with proven stock analysis - Jammu Links News
What makes Intellia Therapeutics Inc. stock price move sharplyUnlock daily market insights for better decisions - Jammu Links News
How does Intellia Therapeutics Inc. compare to its industry peersFree Predictions - Jammu Links News
What catalysts could drive Intellia Therapeutics Inc. stock higher in 2025Breakout portfolio performance - Jammu Links News
Intellia Therapeutics Offers Inducement Grants Amidst Employment Expansion Amidst Challenges in Financial Health and Business Performance - AInvest
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Intellia Therapeutics Inc Azioni (NTLA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
| BASTA JAMES | EVP, General Counsel |
Jan 03 '25 |
Sale |
12.18 |
7,074 |
86,161 |
74,497 |
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):